Elenestinib

{
  "id": "MLC-T-ONC-013300",
  "term": "Elenestinib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable protein tyrosine kinase inhibitor of the mutated form of the tumor-associated antigen (TAA) mast/stem cell factor receptor c-Kit (SCFR), D816V, with potential antineoplastic activity. Upon oral administration, elenestinib binds to and inhibits the specific c-Kit mutant D816V. This may result in an inhibition of cell proliferation in mast cells that overexpress this c-Kit mutation. D816V, a mutation in which the amino acid asparagine aspartic acid at position 816 in the mast/stem cell growth factor receptor Kit protein is replaced by valine, may drive mastocytosis and other mast cell disorders.",
  "synonyms": [
    "D816V-mutant KIT inhibitor BLU-263",
    "KIT D816V mutant-selective inhibitor BLU-263"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/elenestinib/"
}